Health Mart and APCI engage lawmakers for Florida Independent Pharmacy Day
LAKELAND, Fla. — Florida Independent Pharmacy Day celebrates the contributions of independent pharmacists in reducing healthcare costs and improving patient care. Health Mart and American Pharmacy Cooperative have invited Florida legislators to visit pharmacies across Florida on Oct. 27 to highlight independent pharmacy’s unique contributions and impact on healthcare in communities around the state.
“American Pharmacists Month draws attention to the fact that pharmacists are consistently voted one of the most trusted healthcare professionals, as well as the most accessible healthcare provider in communities across the nation,” stated Chris Dimos, SVP marketing and business strategy, McKesson U.S. Pharmaceutical. “With a variety of public policy issues and legislation impacting the independent pharmacy – and by extension, patients across the state of Florida – we felt it was important to kickstart a dialogue with Florida legislators about the critical role independent pharmacists play every day.”
State Rep. Jay Trumbull, representing Florida’s 6th District, is just one of the legislators supporting his local independent pharmacy, Coopers Drugs in Panama City. Trumbull’s office toured Coopers Drugs and visited with staff to begin an ongoing conversation regarding potential legislation in the state. The visit will launch efforts in October, with more than 20 independent pharmacists participating statewide on Oct. 27, with additional support from APCI.
“APCI supports Main Street America and interaction with elected officials, because lack of involvement in healthcare policymaking empowers others to determine your future,” said Bill Eley, director of legislative affairs, APCI.
Health Mart and APCI support Florida independent pharmacists, like Aneesh Lakhani, in engaging legislation and showcase the role pharmacists play in improving patient outcomes.
“October is a time for us to celebrate pharmacy in general and it also gives us an opportunity to display all the different things we do,” noted Lakhani, owner and head pharmacist at Garden Drug in Oakland Park. “So many people rely on their independent pharmacist as their go-to person for healthcare. We want to showcase the services of local pharmacists for legislators so they can see firsthand how we are out there, every day, fighting to improve the healthcare outcomes of our patients.”
GSK Vaccines set to bring Shingrix, the latest shingles vaccination innovation, to market
LONDON — GlaxoSmithKline on Friday announced that the Food and Drug Administration has approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.
"Shingrix represents a significant scientific advancement in the field of vaccinology," stated Thomas Breuer, SVP and chief medical officer, GSK Vaccines. "The vaccine has shown over 90% efficacy across all age groups in the prevention of shingles, a painful and potentially serious disease that affects one in tnree people in the United States. The risk and severity of shingles increases with age as the immune system loses the ability to mount a strong and effective response to infection. Shingrix was developed specifically to overcome the age-related decline in immunity."
Following this approval from FDA, and pending a recommendation from ACIP, Shingrix will be available shortly.
On Oct. 13, Shingrix was approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Regulatory filings in the European Union, Australia and Japan are underway.
FDA approves new Bydureon formulation, auto-injector
SILVER SPRING, Md. — The Food and Drug Administration has approved an auto-injector and new formulation of a once-weekly treatment for Type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with Type 2 diabetes whose blood sugar is uncontrolled on one or more oral medicines.
Bydureon BCise features a continuous-release delivery system that provides consistent levels of the product’s active ingredient, exenatide, to help patients maintain glycemic control, the company said. The new formulation in the Bydureon BCise device also has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.
“We know that physicians have established longstanding confidence in the significant HbA1c reduction Bydureon provides their patients to help achieve consistent control, with the added benefit of weight loss,” AstraZeneca US president and EVP North America Ruud Dobber said. “With the approval of Bydureon BCise, we’re now introducing a new formulation in an improved, easy-to-use device, that will help enhance the patient experience.”
The company plans to launch Bydureon BCise in the first quarter of 2018 while keeping the Bydureon pen available for patients.